ER ER ER ER - Endocrine Reviews

REFERENCES
1. Group EBCTC 1998 Tamoxifen for early breast cancer: an overview of the
randomised trials. Lancet 351:1451-67
2. Gradishar WJ 2004 Tamoxifen--what next? Oncologist 9:378-84
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin
WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-
Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer:
report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J
Natl Cancer Inst 90:1371-88.
4. Osborne CK, Schiff R 2005 Aromatase inhibitors: future directions. J Steroid
Biochem Mol Biol 95:183-7
5. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M
2003 Integration of signal transduction inhibitors with endocrine therapy: an
approach to overcoming hormone resistance in breast cancer. Clin Cancer Res
9:524S-32S
6. Lonning PE 2004 Aromatase inhibitors in breast cancer. Endocr Relat Cancer
11:179-89
7. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud
T 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen
alone for adjuvant treatment of postmenopausal women with early breast cancer:
first results of the ATAC randomised trial. Lancet 359:2131-9
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione
M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
41